Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The strategy for combining therapeutic agents in cancer treatments has been successful in
multiple tumor types, including NSCLC. Erlotinib and bevacizumab target different pathways
involved in tumor growth. Nonclinical studies have demonstrated that the combination of
bevacizumab and erlotinib results in greater efficacy than either agent alone. Furthermore,
because there is little to no overlap in toxicity profile between the two agents, the
combination is expected to be well tolerated and may provide even greater benefit for
patients who are unable to receive cytotoxic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Nasser Hanna, M.D.
Collaborators:
Genentech, Inc. Hoosier Cancer Research Network Walther Cancer Institute